

## Special Issue

# Current Status of Monkeypox Vaccines

### Message from the Guest Editor

Monkeypox disease has received some increased attention in the United States recently. This special issue will review the epidemiology, clinical manifestations in animals and humans, molecular biology of the virus, and vaccine considerations, including mechanisms of action, adverse effects, as well as the status of new and proposed vaccines. The current animal vectors and clinical trial data in humans will be reviewed. In this Special Issue, original research articles, reviews, as well as significant case reports are welcome. Research areas may include (but not limited to) the following:

- Monkeypox virus
- Monkeypox disease
- Animal vectors
- Molecular biology of the virus
- Vaccine mechanisms of action

We look forward to receiving your contributions. Prof. Dr. Lawrence D. Frenkel

---

### Guest Editor

Prof. Dr. Lawrence Frenkel  
St. Peter's University Hospital, New Brunswick, NJ, USA

---

### Deadline for manuscript submissions

closed (30 November 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/167574](https://mdpi.com/si/167574)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).